Levi & Korsinsky announces it has commenced an investigation of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ:BIIB) concerning possible violations of federal securities laws.

In an April 21, 2016 SEC filing, Biogen acknowledged receipt of a subpoena from the federal government requesting documents related to the Company’s relationship with non-profit organizations that provide assistance to patients taking drugs sold by the Company. On May 27, 2016, Bloomberg reported that Biogen is one of three major drugmakers to disclose in a recent SEC filing the receipt of a subpoena as part of this expanding federal investigation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/biib

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.